Condition
Mesothelioma, Malignant
Estimated Enrollment: 108
Age Group: 18 Years to 99 Years (Adult, Senior)
Gender: All
Study Type: Interventional
Study Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment
Study ID Numbers: MORAb-009-201
Study First Received: January 14, 2015
Last Updated: February 8, 2017
Estimated Primary Completion Date: September 2017
Primary Outcome Measures:
Overall Survival (OS)|Progression Free Survival (PFS)|Objective Response Rate [ORR]|Duration of response (DR)|Disease control rates (DCR)|Duration of disease control (DDC)|Health related quality of life (QOL)|Duration of Performance Status Maintenance (DPSM)|Safety and tolerability as a measure of number of participants with Adverse Events (AEs)/Serious Adverse Events (SAEs)|Pharmacokinetic (PK) and pharmacodynamic (PD) profile
Sponsors and Collaborators:
Morphotek
Website Link: https://ClinicalTrials.gov/show/NCT02357147
